Fate Therapeutics (FATE) Tops Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. SPY
5. ANT
6. META
7. BA
8. INTC
9. JBLU
10. AAPL

Go back to Fate Therapeutics (FATE) Tops Q3 EPS by 2c

Fate Therapeutics Reports Third Quarter 2016 Financial Results

November 7, 2016 4:01 PM EST

IND Filed for FATE-NK100 Adaptive Natural Killer Cell Immunotherapy in Acute Myeloid Leukemia

Orphan Drug Designations for ProTmune Granted by FDA and EMA

ProTmune PROTECT Clinical Protocol Amended to Facilitate Path for Accelerated Registration

SAN DIEGO, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2016.

During the quarter, we made substantial progress... More